Results 171 to 180 of about 25,216 (236)

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Radiotherapy (RT) constitutes an important treatment modality in multiple myeloma (MM), traditionally used for the management of symptomatic osteolytic and extramedullary lesions. Objectives of RT are symptom alleviation and prevention of complications such as neurological deficits and pathological fractures.
Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, David Rene Steike, Sebastian Lohmann, Stefan Gravemeyer, Matthias Stelljes, Georg Lenz, Hans Theodor Eich, Michael Oertel   +9 more
wiley   +1 more source

Removal of Aggregates During Bispecific Antibody Purification Using Hydrophobic Interaction Chromatography. [PDF]

Membranes (Basel)
Zhao P, Qi Y, Gao K.
europepmc   +1 more source

Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions

MedComm, Volume 7, Issue 3, March 2026.
Immune exhaustion is a well‐established hallmark of both cancer and chronic infection. This review proposes a novel “infection–exhaustion–tumor axis” framework, wherein chronic pathogens (e.g., oncogenic viruses) evade immune surveillance by hijacking inflammatory signaling to drive immune cell exhaustion, thereby creating immunosuppressive niches ...
Yali Song, Yazhi Mo, Si Chen, Yuemei Chen, Chunying Zhang, Shanying Deng, Juan Liao, Yi He, Wei Wang, Weidong Zheng, Tingting Zeng   +10 more
wiley   +1 more source

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. [PDF]

Biomolecules
Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, Um W.   +6 more
europepmc   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Meta-analysis of comparing CAR-T and bispecific antibody therapy in relapsed/refractory indolent B-cell non-Hodgkin's lymphomas. [PDF]

J Transl Med
Zhang MY, Cai YM, Zhu XQ, Lu KJ, Shen LJ, Du J.   +5 more
europepmc   +1 more source

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing

The Journal of Pathology, Volume 268, Issue 3, Page 249-262, March 2026.
Abstract Netherton syndrome (NS) is a rare, severe, and often life‐threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities.
Eleni Zingkou, Evangelos Bisyris, Georgios Pampalakis, Georgia Sotiropoulou   +3 more
wiley   +1 more source

Characterization of free light chain impurity in a bispecific antibody. [PDF]

MAbs
Sadek M, Mantha N, Lippold S, Li D, Spitler K, Li R, Spinosa P, Liu B, Luu S, Woon N, Zhang Y, Guo J, Yang R, Zarzar J, Yang Y.   +14 more
europepmc   +1 more source

Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements, Julia Mesawich, Cassandra Twisdale   +2 more
wiley   +1 more source

Phase 1 dose-escalation study of IBI324, a VEGF-A/Ang-2 bispecific antibody, for the treatment of diabetic macular oedema. [PDF]

BMJ Open Ophthalmol
Wang Z, Sun J, Liu K, Tao L, Liu Q, Wu M, Lu S, Deng J, Li L, Qian L, Li X, Sun X.   +11 more
europepmc   +1 more source